Drugs

Make plans to keep your medicines safe

Aug 28 - Be prepared for fire, flood, natural disasters, and power loss

Learn More

Rare, severe lung issue with certain breast cancer drugs

Sep 13 - Watch for breathing symptoms with Ibrance, Kisqali and Verzenio

FDA investigating impurities found in some ranitidine drugs

Sep 13 - Patients wishing to discontinue use may consider other treatments

2019 OGD/SBIA Complex Genetic Drug Product Development Workshop

Do you research and develop complex generic drugs?

Sep 25-26 - Register to learn how FDA research guides, facilitates this process

Drug Information, Safety, and Availability

Medication Guides, Drug Safety Communications, Shortages, Recalls

Drug Approvals and Databases

Drugs@FDA, Orange Book, National Drug Code, Recent drug approvals

Drug Development and Review Process

Drug applications, submissions, manufacturing, and small business help

Guidance, Compliance & Regulatory Information

Guidances, warning letters, drug compounding, registration and listing

Regulatory Science Research and Education

CDER research programs, initiatives, resources, and CDERLearn education

Emergency Preparedness

Prepare and respond to natural disasters, nuclear and chemical attacks

Updates, News, and Events

Recent approvals, meetings, workshops, blogs, podcasts, stay connected

About the Center for Drug Evaluation and Research (CDER)

Our role, mission, organization, history, leadership, job openings

Consumers and Patients

Find drug information. Report drug side effects. Learn how to buy, use, and dispose of unused drugs. Attend a public meeting.

Health Care Professionals

Get drug safety, recall, and shortage information. Report drug adverse events. Find jobs at FDA. Watch training/education videos and courses.

Industry

Search drug databases. Find guidance, submission, user fee, and meeting information. Get small business assistance. Find jobs at FDA.

Opioids

Reducing the impact of opioid misuse and abuse

Generics

Ensuring access to safe, affordable, and effective generic drugs

Warning Letters

Warning and Notice of Violation Letters to Pharmaceutical Companies

Guidances

FDA's current thinking on drug development and review activities

Drug Development Tools Qualification Program

Using scientific and technical innovations for better drug development

21st Century Cures at CDER

Bringing innovative and advanced medicines to patients faster

Expanded Access (Compassionate Use)

Providing access to investigational drugs outside of clinical trials

Director's Corner

CDER Center Director Dr. Janet Woodcock speaking on drug-related topics

Sep 13

FDA Updates and Press Announcements on NDMA in Zantac (ranitidine)

Sep 13

FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer

Aug 28

FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)

Drug Safety Announcements

Center

Sep 16

Fitoterapia USA Inc. Issues Voluntary Nationwide Recall of MERO MACHO ARTIFICIAL PASSION FRUIT FLAVORED VITAMIN C LIQUID SUPPLEMENT Due to Presence of Active Ingredient Tadalafil

Sep 12

Darmerica LLC Issues Voluntary Nationwide Recall of Quinacrine Dihydrochloride Due to A Labeling Error

Sep 12

KRS Global Biotechnology, Inc. Issues Voluntary Nationwide Recall of All Human and Animal Sterile Drug Products Due to Lack of Assurance of Sterility

Center

Sep 17

FDA takes first action under new international collaboration with Australia and Canada designed to provide a framework for concurrent review of cancer therapies, approving treatment for patients with endometrial carcinoma

Sep 13

Statement alerting patients and health care professionals of NDMA found in samples of ranitidine

More Press Announcements

Office of Communications
10001 New Hampshire Ave
Hillandale Building, 4th Fl
Silver Spring, MD 20993

druginfo@fda.hhs.gov

Toll Free

(855) 543-3784

(301) 796-3400

Hours Available

CDER Division of Drug Information

U.S. Food and Drug Administration

Drugs

The Center for Drug Evaluation and Research (CDER) ensures that safe and effective drugs are available to improve the health of the people in the United States

Make plans to keep your medicines safe

Rare, severe lung issue with certain breast cancer drugs

FDA investigating impurities found in some ranitidine drugs

Do you research and develop complex generic drugs?

Navigate the Drugs Section

Drug Information, Safety, and Availability

Drug Approvals and Databases

Drug Development and Review Process

Guidance, Compliance & Regulatory Information

Regulatory Science Research and Education

Emergency Preparedness

Updates, News, and Events

About the Center for Drug Evaluation and Research (CDER)

Resources for You

Consumers and Patients

Health Care Professionals

Industry

Priority Areas & Initiatives

Opioids

Generics

Warning Letters

Guidances

Drug Development Tools Qualification Program

21st Century Cures at CDER

Expanded Access (Compassionate Use)

Director's Corner

Drug Safety Announcements

FDA Updates and Press Announcements on NDMA in Zantac (ranitidine)

FDA warns about rare but severe lung inflammation with Ibrance, Kisqali, and Verzenio for breast cancer

FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR)

Drug-related Recall Announcements

Fitoterapia USA Inc. Issues Voluntary Nationwide Recall of MERO MACHO ARTIFICIAL PASSION FRUIT FLAVORED VITAMIN C LIQUID SUPPLEMENT Due to Presence of Active Ingredient Tadalafil

Darmerica LLC Issues Voluntary Nationwide Recall of Quinacrine Dihydrochloride Due to A Labeling Error

KRS Global Biotechnology, Inc. Issues Voluntary Nationwide Recall of All Human and Animal Sterile Drug Products Due to Lack of Assurance of Sterility

Drug-related Press Announcements

FDA takes first action under new international collaboration with Australia and Canada designed to provide a framework for concurrent review of cancer therapies, approving treatment for patients with endometrial carcinoma

Statement alerting patients and health care professionals of NDMA found in samples of ranitidine